Roxindole (INNTooltip International Nonproprietary Name; developmental code name EMD-49980) is a dopaminergic and serotonergic drug which was under development for the treatment of major depressive disorder, obsessive–compulsive disorder (OCD), panic disorder, and psychotic disorders like schizophrenia but was never marketed.
Pharmacology
Pharmacodynamics Roxindole acts as an agonist at the following receptors:
D2 receptor (Ki = 2.82 nM) D3 receptor (Ki = 1.17 nM) D4 receptor (Ki = 5.89 nM) 5-HT1A receptor (Ki = 0.380 nM) At D2 and possibly D3 receptors roxindole is a partial agonist with preferential actions at autoreceptors and has been touted as a 'selective' autoreceptor agonist, hence the justification of its application as an antipsychotic. It shows markedly lower affinity for the serotonin 5-HT1B and 5-HT1D receptors and acts as a weak partial agonist of these receptors. It is also a serotonin reuptake inhibitor (IC50 = 1.4 nM) and has been reported to act as a 5-HT2A receptor antagonist as well.
History and development Roxindole was originally developed by Merck KGaA for the treatment of schizophrenia. In clinical trials its antipsychotic efficacy was only modest but it was unexpectedly found to produce potent and rapid antidepressant and anxiolytic effects. As a result, roxindole was further researched for the treatment of depression instead. It has also been investigated as a therapy for Parkinson's disease and prolactinoma. However, it has never been marketed. The drug reached phase 3 clinical trials prior to the discontinuation of its development.
See also List of investigational antidepressants List of investigational antipsychotics List of investigational obsessive–compulsive disorder drugs List of investigational panic disorder drugs Carmoxirole Dimethylhomotryptamine
References


